CR20150153A - Tratamiento para artitris reumatoide - Google Patents

Tratamiento para artitris reumatoide

Info

Publication number
CR20150153A
CR20150153A CR20150153A CR20150153A CR20150153A CR 20150153 A CR20150153 A CR 20150153A CR 20150153 A CR20150153 A CR 20150153A CR 20150153 A CR20150153 A CR 20150153A CR 20150153 A CR20150153 A CR 20150153A
Authority
CR
Costa Rica
Prior art keywords
treatment
artitris
reumatoid
rheumatoid arthritis
csf antibodies
Prior art date
Application number
CR20150153A
Other languages
English (en)
Inventor
Stefan Haertle
Stephane Leclair
Amgad Shebl
Stefan Steidl
Original Assignee
Janssen Pharmaceutica Nv
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv, Morphosys Ag filed Critical Janssen Pharmaceutica Nv
Publication of CR20150153A publication Critical patent/CR20150153A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención proporciona anticuerpos anti-GM-CSFpara utilizarse en el tratamiento de artritis reumatoide. Losanticuerpos anti-GM-CSF, en particular MOR103, se administran alos pacientes que padezcan de artritis reumatoide en dosificaciones que sean benéficas en una situación clínica
CR20150153A 2012-09-20 2015-03-20 Tratamiento para artitris reumatoide CR20150153A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12185235 2012-09-20
US201261703871P 2012-09-21 2012-09-21
PCT/EP2013/069501 WO2014044768A1 (en) 2012-09-20 2013-09-19 Treatment for rheumatoid arthritis

Publications (1)

Publication Number Publication Date
CR20150153A true CR20150153A (es) 2015-09-14

Family

ID=46963526

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20150153A CR20150153A (es) 2012-09-20 2015-03-20 Tratamiento para artitris reumatoide

Country Status (22)

Country Link
US (4) US20150246969A1 (es)
EP (3) EP3345923A1 (es)
JP (4) JP2015533806A (es)
KR (4) KR20240091288A (es)
CN (2) CN109999195A (es)
AU (2) AU2013320261A1 (es)
BR (1) BR112015006189B1 (es)
CL (2) CL2015000696A1 (es)
CR (1) CR20150153A (es)
DO (1) DOP2015000070A (es)
EA (1) EA031489B1 (es)
HK (1) HK1208231A1 (es)
IL (1) IL237554B (es)
IN (1) IN2015KN00657A (es)
MA (1) MA37946B1 (es)
MX (2) MX382937B (es)
MY (1) MY175388A (es)
PE (1) PE20151079A1 (es)
PH (1) PH12015500591B1 (es)
SG (2) SG10201803778PA (es)
UA (1) UA117228C2 (es)
WO (1) WO2014044768A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA37946B1 (fr) * 2012-09-20 2018-09-28 Morphosys Ag Utilisation d’un anticorps anti-gm-csf pour le traitement de la polyarthrite rhumatoïde
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
WO2014068029A1 (en) * 2012-10-31 2014-05-08 Takeda Gmbh Lyophilized formulation comprising gm-csf neutralizing compound
US10745475B2 (en) * 2013-08-30 2020-08-18 Takeda Gmbh Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
WO2015138638A1 (en) * 2014-03-11 2015-09-17 Theraly Pharmaceuticals, Inc. Long acting trail receptor agonists for treatment of autoimmune diseases
KR102385802B1 (ko) 2014-05-07 2022-04-13 다케다 야쿠힝 고교 가부시키가이샤 Gm-csf 중화 화합물을 포함하는 액체 제제
GB201519331D0 (en) * 2015-11-02 2015-12-16 Glaxosmithkline Ip Dev Ltd Treatment paradigm
US11007251B2 (en) 2015-12-17 2021-05-18 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
EA201892260A1 (ru) 2016-04-07 2019-03-29 Дзе Джонс Хопкинс Юниверсити Композиции и способы для лечения панкреатита и боли с применением агонистов рецептора смерти
SG11201901789WA (en) 2016-09-19 2019-03-28 I Mab Anti-gm-csf antibodies and uses thereof
EP3623382A1 (en) 2018-09-14 2020-03-18 Universität Zürich Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
WO2021204649A1 (en) 2020-04-06 2021-10-14 Glaxosmithkline Intellectual Property Development Limited Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome
WO2025218746A1 (en) * 2024-04-17 2025-10-23 Sinomab Bioscience Limited Methods of treating rheumatoid arthritis

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
AU4344697A (en) 1996-10-04 1998-04-24 Amgen, Inc. Pharmaceutical compositions containing an mpl ligand
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
RU2447085C2 (ru) * 2005-05-18 2012-04-10 МорфоСис АГ Анти-gm-csf антитела и их применение
AU2006295340B2 (en) 2005-08-05 2010-11-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
US9399061B2 (en) * 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
WO2008042261A2 (en) * 2006-09-28 2008-04-10 Elusys Therapeutics, Inc. Anti-anthrax antibody, formulations thereof, and methods of use
EP2101780B1 (en) * 2006-11-21 2013-10-09 Kalobios Pharmaceuticals, Inc. Methods of treating chronic inflammatory diseases using a gm-csf antagonist
CA2682292A1 (en) * 2007-03-30 2008-10-09 Medimmune, Llc Aqueous formulation comprising an anti-human interferon alpha antibody
AR065910A1 (es) * 2007-04-02 2009-07-08 Genentech Inc Marcadores biologicos pronosticos de la respuesta de la artritis reumatoide a los antagonistas de los linfocitos b
PL2142174T3 (pl) 2007-04-05 2011-08-31 Sandoz Ag Stabilne wodne preparaty G-CSF
US20090004189A1 (en) * 2007-06-18 2009-01-01 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
CN104072613A (zh) 2007-11-13 2014-10-01 Evec股份有限公司 与hGM-CSF结合的单克隆抗体及包含它的药物组合物
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
CA2747206C (en) * 2008-12-22 2018-04-24 The University Of Melbourne Pain treatment
CN102271705A (zh) 2008-12-22 2011-12-07 墨尔本大学 骨关节炎治疗
JP2010241718A (ja) 2009-04-03 2010-10-28 Kyowa Hakko Kirin Co Ltd 安定な抗体の水溶液製剤
US20120116059A1 (en) * 2009-05-05 2012-05-10 Morphosys Ag Treatment For M Treatment For Multiple Sclerosis
ES2432160T3 (es) 2009-12-31 2013-12-02 Arven Ilac Sanayi Ve Ticaret A.S. Procedimiento novedoso para preparar G-CSF (factor estimulante de colonias de granulocitos)
NZ602685A (en) * 2010-03-01 2014-10-31 Cytodyn Inc Concentrated protein formulations and uses thereof
CN103827143A (zh) 2011-07-06 2014-05-28 莫弗系统股份公司 抗cd20抗体和抗gm-csf抗体的治疗性组合产品及其用途
MA37946B1 (fr) * 2012-09-20 2018-09-28 Morphosys Ag Utilisation d’un anticorps anti-gm-csf pour le traitement de la polyarthrite rhumatoïde

Also Published As

Publication number Publication date
UA117228C2 (uk) 2018-07-10
CN104995210A (zh) 2015-10-21
MA37946A1 (fr) 2018-01-31
US20240417455A1 (en) 2024-12-19
JP2018138551A (ja) 2018-09-06
MY175388A (en) 2020-06-23
SG11201501595YA (en) 2015-05-28
US10913792B2 (en) 2021-02-09
MX2015003644A (es) 2015-09-25
EA031489B1 (ru) 2019-01-31
MA37946B1 (fr) 2018-09-28
KR20220028177A (ko) 2022-03-08
CA2884124A1 (en) 2014-03-27
SG10201803778PA (en) 2018-06-28
EP3916013A1 (en) 2021-12-01
CL2015000696A1 (es) 2015-10-23
JP2024156992A (ja) 2024-11-06
KR20240091288A (ko) 2024-06-21
EA201590359A1 (ru) 2015-08-31
CL2018000933A1 (es) 2018-07-20
CN109999195A (zh) 2019-07-12
US20150246969A1 (en) 2015-09-03
WO2014044768A1 (en) 2014-03-27
AU2016250388A1 (en) 2016-11-17
AU2016250388B2 (en) 2018-07-19
BR112015006189A2 (pt) 2019-11-26
JP2022169709A (ja) 2022-11-09
BR112015006189B1 (pt) 2022-04-05
JP2015533806A (ja) 2015-11-26
US20180230208A1 (en) 2018-08-16
EP2897977A1 (en) 2015-07-29
IL237554B (en) 2019-12-31
MX382937B (es) 2025-03-13
IN2015KN00657A (es) 2015-07-17
AU2013320261A1 (en) 2015-04-09
US20210130451A1 (en) 2021-05-06
MX2021006111A (es) 2021-07-07
DOP2015000070A (es) 2015-08-16
PE20151079A1 (es) 2015-08-07
IL237554A0 (en) 2015-04-30
PH12015500591A1 (en) 2015-05-11
KR20150056846A (ko) 2015-05-27
KR20230041086A (ko) 2023-03-23
HK1208231A1 (en) 2016-02-26
EP3345923A1 (en) 2018-07-11
PH12015500591B1 (en) 2015-05-11

Similar Documents

Publication Publication Date Title
CR20150153A (es) Tratamiento para artitris reumatoide
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
CY1122073T1 (el) Μορια αντισωματος που εχουν εξειδικευση για τον ανθρωπινο οχ40
PL3791896T3 (pl) Terapia skojarzona obejmująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu
TN2015000396A1 (en) Antibody drug conjugates
MA34091B1 (fr) Anticorps anti-cd40
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
PE20150002A1 (es) Anticuerpos anti-fcrn
EA201400178A1 (ru) Лечение рака молочной железы
UA113403C2 (xx) Спосіб підвищення ефективності folr1 терапії раку
EA201590412A1 (ru) Композиции антител и их применения
MX349224B (es) Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa.
MX2015013066A (es) Usos terapéuticos para anticuerpos contra vegfr1.
ECSP13012481A (es) Composiciones de anticuerpo anti-vegfr-3
EA201790973A1 (ru) A-антагонист в низкой дозировке для лечения adhd и болезни паркинсона
WO2012106473A8 (en) Dosing for treatment with anti-egfl7 antibodies
UA97054C2 (ru) Способ комплексного лечения больных с зависимостью вследствие употребления психоактивных веществ
TN2013000068A1 (en) Anti-vegfr-3 antibody compositions
NZ743656A (en) Methods of treating a tauopathy